Preimplantation genetic screening on day 3 embryos using Comparative Genomic Hybridization (CGH)-array in women of advanced maternal age: a prospective randomised controlled trial

BlueGnome Ltd (UK)0 个研究点目标入组 200 人开始时间: 2010年12月20日最近更新: 2015年1月13日

适应症

试验速览

暂无简介。

•1. Female patients aged between 36 and 43 years undergoing an in vitro fertilisation (IVF)/intracytoplasmic sperm injection (ICSI) attempt at the GENERA centre for Reproductive Medicine in Rome
•2. History of less than 3 consecutive miscarriages and no more than 2 failed IVF/ICSI cycles
•3. Greater than or equal to 6 metaphase II (MII) oocytes retrieved
•4. Signed consent form

•1. Azoospermic male partner
•2. Severe male factor infertility defined as ejaculate sperm of less than 1 million sperm/ml
•3. Hydrosalpinx
•4. Polycystic ovarian syndrome (PCOS)
•5. Preimplantation genetic diagnosis (PGD) cycles for monogenic defects and/or chromosomal structural abnormalities
•6. Female patients with pathological uterine cavity
•7. Number of retrieved MII oocytes below 6
•8. Known American Society for Reproductive Medicine (ASRM) Grade III or IV endometriosis
•9. Maternal disease that is not clinically stable and known to impact the ability to become pregnant or carry a pregnancy to term
•9.1. Lupus
•9.2. Chronic liver or kidney disease
•9.3. Body mass index (BMI) greater than 30
•9.4. Uncontrolled hypertension
•9.5. Anti-phospholipid antibody
•9.6. Thrombophilia
•9.7. Insulin dependent diabetes

发起方

BlueGnome Ltd (UK)